David Garrido, Virginia Bove, Fiorella Villano, Eloísa Riva
{"title":"新诊断的多发性骨髓瘤患者在前线自体干细胞移植后的实际生存情况分析。","authors":"David Garrido, Virginia Bove, Fiorella Villano, Eloísa Riva","doi":"10.14712/18059694.2024.4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Autologous stem cell transplantation (ASCT) is the standard consolidation option for transplant-eligible patients with multiple myeloma (MM). The aim of this study is to report the overall survival (OS) and progression-free survival (PFS) outcomes after frontline ASCT in newly-diagnosed MM (NDMM) patients in a real-world setting.</p><p><strong>Methods: </strong>We conducted a retrospective, survival analysis of all NDMM patients included in the MM Uruguayan Registry.</p><p><strong>Results: </strong>We included 151 NDMM patients treated with induction therapy followed by high-dose melphalan and ASCT as consolidation. The median age at diagnosis was 59 years, and the international staging system (ISS) risk groups were ISS-III 32.9%, ISS-II 37.8%, and ISS-I 29.4%. Frontline induction regimens included bortezomib in 61.6% of cases, and maintenance therapy was used in 63.9% of reported cases. With a median follow-up of 42 months, the 36-month OS and PFS for the whole group were 82.4% (95% CI 75.9% to 89.4%) and 63.8% (95% CI 55.6% to 73.3%), respectively, median OS of 98 months and median PFS of 47 months. The 100-month OS and PFS for the entire group were 48.0% (95% CI 34.9% to 66.0%) and 17.3% (95% CI 8.4% to 35.8%), respectively.</p><p><strong>Conclusion: </strong>ASCT is a feasible, safe, and potent strategy that provides a prolonged median OS and PFS in NDMM patients. This approach can be implemented in low-income countries.</p>","PeriodicalId":101400,"journal":{"name":"Acta medica (Hradec Kralove)","volume":"66 3","pages":"117-121"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.\",\"authors\":\"David Garrido, Virginia Bove, Fiorella Villano, Eloísa Riva\",\"doi\":\"10.14712/18059694.2024.4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Autologous stem cell transplantation (ASCT) is the standard consolidation option for transplant-eligible patients with multiple myeloma (MM). The aim of this study is to report the overall survival (OS) and progression-free survival (PFS) outcomes after frontline ASCT in newly-diagnosed MM (NDMM) patients in a real-world setting.</p><p><strong>Methods: </strong>We conducted a retrospective, survival analysis of all NDMM patients included in the MM Uruguayan Registry.</p><p><strong>Results: </strong>We included 151 NDMM patients treated with induction therapy followed by high-dose melphalan and ASCT as consolidation. The median age at diagnosis was 59 years, and the international staging system (ISS) risk groups were ISS-III 32.9%, ISS-II 37.8%, and ISS-I 29.4%. Frontline induction regimens included bortezomib in 61.6% of cases, and maintenance therapy was used in 63.9% of reported cases. With a median follow-up of 42 months, the 36-month OS and PFS for the whole group were 82.4% (95% CI 75.9% to 89.4%) and 63.8% (95% CI 55.6% to 73.3%), respectively, median OS of 98 months and median PFS of 47 months. The 100-month OS and PFS for the entire group were 48.0% (95% CI 34.9% to 66.0%) and 17.3% (95% CI 8.4% to 35.8%), respectively.</p><p><strong>Conclusion: </strong>ASCT is a feasible, safe, and potent strategy that provides a prolonged median OS and PFS in NDMM patients. This approach can be implemented in low-income countries.</p>\",\"PeriodicalId\":101400,\"journal\":{\"name\":\"Acta medica (Hradec Kralove)\",\"volume\":\"66 3\",\"pages\":\"117-121\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta medica (Hradec Kralove)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14712/18059694.2024.4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica (Hradec Kralove)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14712/18059694.2024.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言:自体干细胞移植(ASCT)是符合移植条件的多发性骨髓瘤(MM)患者的标准巩固治疗方案。本研究旨在报告真实世界中新诊断的多发性骨髓瘤(NDMM)患者接受一线ASCT治疗后的总生存期(OS)和无进展生存期(PFS)结果:我们对乌拉圭MM登记处纳入的所有NDMM患者进行了回顾性生存分析:结果:我们纳入了151名接受诱导治疗的NDMM患者,他们在接受诱导治疗后又接受了大剂量美罗啡和ASCT作为巩固治疗。确诊时的中位年龄为59岁,国际分期系统(ISS)风险组别为ISS-III组32.9%、ISS-II组37.8%和ISS-I组29.4%。61.6%的病例采用了包括硼替佐米在内的前线诱导疗法,63.9%的报告病例采用了维持疗法。中位随访时间为42个月,全组36个月的OS和PFS分别为82.4%(95% CI 75.9%至89.4%)和63.8%(95% CI 55.6%至73.3%),中位OS为98个月,中位PFS为47个月。整组患者的100个月OS和PFS分别为48.0%(95% CI为34.9%至66.0%)和17.3%(95% CI为8.4%至35.8%):ASCT是一种可行、安全且有效的策略,可延长NDMM患者的中位OS和PFS。这种方法可以在低收入国家实施。
Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.
Introduction: Autologous stem cell transplantation (ASCT) is the standard consolidation option for transplant-eligible patients with multiple myeloma (MM). The aim of this study is to report the overall survival (OS) and progression-free survival (PFS) outcomes after frontline ASCT in newly-diagnosed MM (NDMM) patients in a real-world setting.
Methods: We conducted a retrospective, survival analysis of all NDMM patients included in the MM Uruguayan Registry.
Results: We included 151 NDMM patients treated with induction therapy followed by high-dose melphalan and ASCT as consolidation. The median age at diagnosis was 59 years, and the international staging system (ISS) risk groups were ISS-III 32.9%, ISS-II 37.8%, and ISS-I 29.4%. Frontline induction regimens included bortezomib in 61.6% of cases, and maintenance therapy was used in 63.9% of reported cases. With a median follow-up of 42 months, the 36-month OS and PFS for the whole group were 82.4% (95% CI 75.9% to 89.4%) and 63.8% (95% CI 55.6% to 73.3%), respectively, median OS of 98 months and median PFS of 47 months. The 100-month OS and PFS for the entire group were 48.0% (95% CI 34.9% to 66.0%) and 17.3% (95% CI 8.4% to 35.8%), respectively.
Conclusion: ASCT is a feasible, safe, and potent strategy that provides a prolonged median OS and PFS in NDMM patients. This approach can be implemented in low-income countries.